{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T15:18:27Z","timestamp":1769527107281,"version":"3.49.0"},"reference-count":60,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1097\/crd.0000000000000022","type":"journal-article","created":{"date-parts":[[2014,3,11]],"date-time":"2014-03-11T14:35:00Z","timestamp":1394548500000},"page":"176-181","source":"Crossref","is-referenced-by-count":18,"title":["Interleukin 1\u03b2"],"prefix":"10.1097","volume":"22","author":[{"given":"Stephanie","family":"McCarty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Frishman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-4-20210203","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/00132580-200109000-00009","article-title":"Systemic inflammation as a cardiovascular disease risk factor and as a potential target for drug therapy.","volume":"3","author":"Kaplan","year":"2001","journal-title":"Heart Dis"},{"key":"R2-4-20210203","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/CRD.0b013e3181885933","article-title":"Vaccines in development to prevent and treat atherosclerotic disease.","volume":"16","author":"Riley","year":"2008","journal-title":"Cardiol Rev"},{"key":"R3-4-20210203","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosisan inflammatory disease.","volume":"340","author":"Ross","year":"1999","journal-title":"N Engl J Med"},{"key":"R4-4-20210203","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/315641a0","article-title":"Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs.","volume":"315","author":"March","year":"1985","journal-title":"Nature"},{"key":"R5-4-20210203","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1136\/jnnp.2004.054882","article-title":"Acute Stroke Investigators. A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients.","volume":"76","author":"Emsley","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R6-4-20210203","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/art.30128","article-title":"Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series.","volume":"63","author":"Nigrovic","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R7-4-20210203","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJMoa065213","article-title":"Interleukin-1-receptor antagonist in type 2 diabetes mellitus.","volume":"356","author":"Larsen","year":"2007","journal-title":"N Engl J Med"},{"key":"R8-4-20210203","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1016\/j.molimm.2007.02.016","article-title":"Phosphorylation of IRF8 in a pre-associated complex with Spi-1PU.1 and non-phosphorylated Stat1 is critical for LPS induction of the IL1B gene.","volume":"44","author":"Unlu","year":"2007","journal-title":"Mol Immunol"},{"key":"R9-4-20210203","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1089\/thy.2007.0296","article-title":"The multiple facets of the fat tissue.","volume":"18","author":"Rocha","year":"2008","journal-title":"Thyroid"},{"key":"R10-4-20210203","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1146\/annurev.immunol.021908.132612","article-title":"Immunological and inflammatory functions of the interleukin-1 family.","volume":"27","author":"Dinarello","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"R11-4-20210203","doi-asserted-by":"crossref","first-page":"e403","DOI":"10.1038\/cddis.2012.144","article-title":"ATP release and purinergic signaling: a common pathway for particle-mediated inflammasome activation.","volume":"3","author":"Riteau","year":"2012","journal-title":"Cell Death Dis"},{"key":"R12-4-20210203","doi-asserted-by":"crossref","first-page":"e11765","DOI":"10.1371\/journal.pone.0011765","article-title":"Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation.","volume":"5","author":"Rajamaki","year":"2010","journal-title":"PLoS One"},{"key":"R13-4-20210203","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/CRD.0b013e3181709fd8","article-title":"Toll-like receptors: new therapeutic targets for the treatment of atherosclerosis, acute coronary syndromes, and myocardial failure.","volume":"16","author":"Erickson","year":"2008","journal-title":"Cardiol Rev"},{"key":"R14-4-20210203","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1182\/blood.V87.6.2095.bloodjournal8762095","article-title":"Biologic basis for interleukin-1 in disease.","volume":"87","author":"Dinarello","year":"1996","journal-title":"Blood"},{"key":"R15-4-20210203","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1161\/01.CIR.102.18.2165","article-title":"Direct proinflammatory effect of C-reactive protein on human endothelial cells.","volume":"102","author":"Pasceri","year":"2000","journal-title":"Circulation"},{"key":"R16-4-20210203","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1161\/01.ATV.20.9.2094","article-title":"C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis.","volume":"20","author":"Torzewski","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R17-4-20210203","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1182\/blood-2002-06-1762","article-title":"Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NF kB-CEBP-B complex formation.","volume":"101","author":"Kleemann","year":"2003","journal-title":"Blood"},{"key":"R18-4-20210203","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/1074-7613(95)90154-X","article-title":"Resistance to fever induction and impaired acute-phase response in interleukin-1 beta-deficient mice.","volume":"3","author":"Zheng","year":"1995","journal-title":"Immunity"},{"key":"R19-4-20210203","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1158\/0008-5472.CAN-06-2956","article-title":"Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors.","volume":"67","author":"Krelin","year":"2007","journal-title":"Cancer Res"},{"key":"R20-4-20210203","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1194\/jlr.R300019-JLR200","article-title":"Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host.","volume":"45","author":"Khovidhunkit","year":"2004","journal-title":"J Lipid Res"},{"key":"R21-4-20210203","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0022-2275(20)41334-3","article-title":"Endotoxin rapidly induces changes in lipid metabolism that produce hypertriglyceridemia: low doses stimulate hepatic triglyceride production while high doses inhibit clearance.","volume":"33","author":"Feingold","year":"1992","journal-title":"J Lipid Res"},{"key":"R22-4-20210203","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/0002-9343(93)90144-E","article-title":"Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B.","volume":"94","author":"Chait","year":"1993","journal-title":"Am J Med"},{"key":"R23-4-20210203","first-page":"915","article-title":"Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity.","volume":"320","author":"Steinberg","year":"1989","journal-title":"N Engl J Med"},{"key":"R24-4-20210203","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2174\/187152508783955006","article-title":"IL-1 cytokines in cardiovascular disease: diagnostic, prognostic and therapeutic implications.","volume":"6","author":"Apostolakis","year":"2008","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"R25-4-20210203","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1084\/jem.160.2.618","article-title":"Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells.","volume":"160","author":"Bevilacqua","year":"1984","journal-title":"J Exp Med"},{"key":"R26-4-20210203","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/nrcardio.2009.228","article-title":"Monocytes in atherosclerosis: subsets and functions.","volume":"7","author":"Woollard","year":"2010","journal-title":"Nat Rev Cardiol"},{"key":"R27-4-20210203","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0021-9150(96)05968-0","article-title":"Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall.","volume":"127","author":"Rus","year":"1996","journal-title":"Atherosclerosis"},{"key":"R28-4-20210203","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2165\/00003495-199856001-00002","article-title":"New insights into plaque stabilization by lipid lowering.","volume":"56","author":"Libby","year":"1998","journal-title":"Drugs"},{"key":"R29-4-20210203","doi-asserted-by":"crossref","first-page":"e24097","DOI":"10.1371\/journal.pone.0024097","article-title":"P2X7 receptor and caspase 1 activation are central to airway inflammation observed after exposure to tobacco smoke.","volume":"6","author":"Eltom","year":"2011","journal-title":"PLoS One"},{"key":"R30-4-20210203","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1172\/JCI200319246","article-title":"Obesity is associated with macrophage accumulation in adipose tissue.","volume":"112","author":"Weisberg","year":"2003","journal-title":"J Clin Invest"},{"key":"R31-4-20210203","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3389\/fimmu.2013.00050","article-title":"Mechanisms of disease: inflammasome activation and the development of type 2 diabetes.","volume":"4","author":"Grant","year":"2013","journal-title":"Front Immunol"},{"key":"R32-4-20210203","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0005-2760(80)90061-2","article-title":"Abnormal effects of hypertriacylglycerolemic very low-density lipoproteins on 3-hydroxy-3-methylglutaryl-CoA reductase activity and viability of cultured bovine aortic endothelial cells.","volume":"618","author":"Gianturco","year":"1980","journal-title":"Biochim Biophys Acta"},{"key":"R33-4-20210203","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0022-2275(20)41629-3","article-title":"Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor.","volume":"32","author":"Nigon","year":"1991","journal-title":"J Lipid Res"},{"key":"R34-4-20210203","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0022-2275(20)42610-0","article-title":"Differential uptake of proteoglycan-selected subfractions of low density lipoprotein by human macrophages.","volume":"31","author":"Hurt-Camejo","year":"1990","journal-title":"J Lipid Res"},{"key":"R35-4-20210203","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.bbrc.2012.07.011","article-title":"Oxidized low-density lipoprotein induces secretion of interleukin-1 by macrophages via reactive oxygen species-dependent NLRP3 inflammasome activation.","volume":"425","author":"Jiang","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"R36-4-20210203","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00392-012-0496-3","article-title":"Relationship between inflammatory markers, oxidant-antioxidant status and intima-media thickness in prepubertal children with juvenile idiopathic arthritis.","volume":"102","author":"Breda","year":"2013","journal-title":"Clin Res Cardiol"},{"key":"R37-4-20210203","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.cell.2010.01.040","article-title":"The inflammasomes.","volume":"140","author":"Schroder","year":"2010","journal-title":"Cell"},{"key":"R39-4-20210203","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.atherosclerosis.2011.02.026","article-title":"Monoclonal antibodies targeting IL-1 beta reduce biomarkers of atherosclerosis in vitro and inhibit atherosclerotic plaque formation in apolipoprotein E-deficient mice.","volume":"216","author":"Bhaskar","year":"2011","journal-title":"Atherosclerosis"},{"key":"R40-4-20210203","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/rheumatology\/kes114","article-title":"Assessing the safety of biologic agents in patients with rheumatoid arthritis.","volume":"51","author":"Rubbert-Roth","year":"2012","journal-title":"Rheumatology"},{"key":"R41-4-20210203","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1471-2431-12-29","article-title":"Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis.","volume":"12","author":"Kemper","year":"2012","journal-title":"BMC Pediatr"},{"key":"R42-4-20210203","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/acr.21901","article-title":"Anakinra in adult onset Stills disease: long term treatment in patients resistant to conventional therapy.","volume":"65","author":"Giampietro","year":"2013","journal-title":"Arthritis Care Res"},{"key":"R43-4-20210203","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000326112","article-title":"Efficacy of anti-interleukin-1 receptor antagonist anakinra (Kineret) in a case of refractory Sweets syndrome.","volume":"222","author":"Kluger","year":"2011","journal-title":"Dermatology"},{"key":"R44-4-20210203","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2337\/dc09-0533","article-title":"Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes.","volume":"32","author":"Larsen","year":"2009","journal-title":"Diabetes Care"},{"key":"R45-4-20210203","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1161\/ATVBAHA.112.300432","article-title":"Genetic and pharmacologic disruption of interleukin-1 signaling inhibits experimental aortic aneurysm formation.","volume":"33","author":"Johnston","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R46-4-20210203","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1038\/jcbfm.2012.101","article-title":"Delayed administration of interleukin-1 receptor antagonist reduces ischemic brain damage and inflammation in comorbid rats.","volume":"32","author":"Pradillo","year":"2012","journal-title":"J Cereb Blood Flow Metab"},{"key":"R47-4-20210203","doi-asserted-by":"crossref","first-page":"A13","DOI":"10.1136\/heartjnl-2011-300198.15","article-title":"Investigation of IL-1 inhibition in patients presenting with non-ST elevation myocardial infarction acute coronary syndromes (the MRC ILA Heart Study).","volume":"97","author":"Morton","year":"2011","journal-title":"Heart"},{"key":"R48-4-20210203","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.amjcard.2013.01.287","article-title":"Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study.","volume":"111","author":"Abbate","year":"2013","journal-title":"Am J Cardiol"},{"key":"R50-4-20210203","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.amjcard.2013.08.047","article-title":"Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study).","volume":"113","author":"Van Tassell","year":"2014","journal-title":"Am J Cardiol"},{"key":"R51-4-20210203","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4161\/mabs.2.1.10328","article-title":"Canakinumab.","volume":"2","author":"Dhimolea","year":"2010","journal-title":"MAbs"},{"key":"R52-4-20210203","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1586\/eci.10.66","article-title":"Canakinumab: a human anti-IL-1 monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes.","volume":"6","author":"Church","year":"2010","journal-title":"Expert Rev Clin Immunol"},{"key":"R53-4-20210203","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1517\/14712598.2013.735657","article-title":"Update on biologicals for treatment of juvenile idiopathic arthritis.","volume":"13","author":"Horneff","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"R54-4-20210203","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1517\/14712598.2012.705825","article-title":"Canakinumab in gout.","volume":"12","author":"Schlesinger","year":"2012","journal-title":"Expert Opin Biol Ther"},{"key":"R55-4-20210203","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/BOR.0b013e3283373fa0","article-title":"Actual status of antiinterleukin-1 therapies in rheumatic diseases.","volume":"22","author":"Geyer","year":"2010","journal-title":"Curr Opin Rheumatol"},{"key":"R56-4-20210203","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/j.1463-1326.2012.01637.x","article-title":"Effect of anti-IL-1 antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial.","volume":"14","author":"Rissanen","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"R57-4-20210203","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1136\/ard.2011.152728","article-title":"Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes.","volume":"70","author":"Kuemmerle-Deschner","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R58-4-20210203","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ahj.2011.06.012","article-title":"Interleukin-1 inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS).","volume":"162","author":"Ridker","year":"2011","journal-title":"Am Heart J"},{"key":"R59-4-20210203","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.CIR.98.9.839","article-title":"Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.","volume":"98","author":"Ridker","year":"1998","journal-title":"Circulation"},{"key":"R60-4-20210203","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM199704033361401","article-title":"Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.","volume":"336","author":"Ridker","year":"1997","journal-title":"N Engl J Med"},{"key":"R61-4-20210203","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(09)61717-7","article-title":"C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis.","volume":"375","author":"Kaptoge","year":"2010","journal-title":"Lancet"},{"key":"R62-4-20210203","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1161\/CIRCULATIONAHA.112.122556","article-title":"CANTOS Pilot Investigative Group. Effects of interleukin-1 inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial.","volume":"126","author":"Ridker","year":"2012","journal-title":"Circulation"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:49:07Z","timestamp":1620949747000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045415-201407000-00004"}},"subtitle":["A Proinflammatory Target for Preventing Atherosclerotic Heart Disease"],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000022","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]}}}